ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO762

Influence of Dialysis Membranes on Bisphenol A Serum Levels in Online Hemodiafiltration

Session Information

Category: Dialysis

  • 601 Standard Hemodialysis for ESRD

Authors

  • Mas, Sebastian, IIS-FJD, Madrid, Spain
  • Bosch, Enrique, IIS- FJD, Madrid, Spain
  • Ruiz, Alberto, IIS- FJD, Madrid, Spain
  • Civantos, Esther, IIS- FJD, Madrid, Spain
  • Egido, Jesus, Fundacion Jimenez Diaz, Madrid, Spain
  • Ortiz, Alberto, Fundacion Jimenez Diaz, Madrid, Spain
  • Gonzalez-parra, Emilio E., Fundacion Jimenez Diaz, Madrid, Spain
Background

In uremia, the environmental toxin Bisphenol A (BPA) accumulates bound to proteins. BPA-containing dialyzers contribute to increase plasma BPA concentration in conventional hemodialysis patients. Online hemodiafiltration (OL-HDF) more efficiently clears high molecular weight molecules, and this may improve BPA clearance. However, OL-HDF requires high infusion volumes of replacement fluid generated online by using BPA-containing membranes and, thus, can be a source of BPA load.

Objectives:To assess plasma BPA levels in OL-HDF patients using BPA-free or BPA-containing dialyzers.

Methods

In a prospective study, plasma BPA was assessed at baseline and 3 months after switching from baseline BPA-free polynephron to BPA-containing polysulfone (n=31) dialyzers, or from baseline polysulfone to polynephron (n=27) dialyzers in OL-HDF patients. Results were compared to a prior study on conventional hemodialysis.

Results

OL-HDF patients had lower plasma BPA than those in conventional hemodialysis (12.12±15.91 vs. 64.55±93.8 ng/mL) and both were several fold higher than healthy controls (<2 ng/ml). However, this was influenced by the dialysis membrane. Thus, baseline BPA was 8.79±7.97 ng/ml in patients dialyzed ≥6 months with polynephron versus 23.42±20.38 ng/mL with polysulfone. During the first single OL-HDF session with the switch membrane, BPA decreased in the polysulfone-to-polynephron group (pre-dialysis 23.42±20.38 ng/ml to post-dialysis 6.44±10.77 ng/mL, p <0.01), but remained unchanged in polynephron-to-polysulfone patients. After 3 months on polysulfone, BPA levels rose non-significantly from 8.79±7.97 to 11.02±16.17 ng/mL in the polynephron-to-polysulfone group, while they decreased 51% in the polysulfone-to-polynephron group (p<0.01).

Conclusion

Optimal reduction in BPA levels is achieved by using OL-HDF with BPA-free dialyzer membranes. Attempts at optimizing net BPA clearance in OL-HDF are justified by the residual higher plasma BPA levels when compared to healthy controls.

Funding

  • Commercial Support